,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny-04', 'breast']
standing ovation for destiny-04 trial with t-dxd in her2 low breast cancer today. practice-changing results, undoubtedly. spectacular os benefit in hr+ and hr- disease. the asco plenary session remains the holy grail of clinical research in our field. 
Passionate medical oncologist with experimental + public health agenda heading the Dpt. of General Medical Oncology + Lab. of Exp. Oncology at UZ/KU Leuven (BE)